ARTICLE | Clinical News
Secnidazole: Phase III data
August 22, 2016 7:00 AM UTC
The double-blind, U.S. Phase III Study 301 in 189 patients ages >=12 with infrequent or recurrent bacterial vaginosis showed that a single dose of 2 g oral Solosec met the primary endpoint of improvin...